SenesTech company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year




Date of IPO


Market Cap


Stock Price


About SenesTech

SenesTech is a biotech company engaged in reproductive physiology. Its aims to develop nonsurgical methods for controlling reproduction in rodent and wildlife populations methods that could per the company profoundly increase food production throughout the world. SenesTech is currently using its chemical compound branded ContraPest to control the Southeast Asian Rice Rat and increase rice production. The first technology of its kind, ContraPest uses species-specific protocols to accelerate the natural depletion of follicles in the mammalian ovary, causing sterility. Follicles are depleted without causing systemic toxicity, adverse side effects, or environmental impacts. Based on technology licensed from the University of Arizona, SenesTech was founded in Flagstaff in 2002. The company recently entered into a strategic alliance with the government of Australia to control rodent populations in Australia, New Zealand, and Southeast Asia. Domestic and international patents are pending.

SenesTech Headquarter Location

2225 East Gemini Drive

Flagstaff, Arizona, 86001,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

SenesTech Patents

SenesTech has filed 4 patents.

The 3 most popular patent topics include:

  • Cluster bombs
  • Dicarboxylic acids
  • Epoxides
patents chart

Application Date

Grant Date


Related Topics




Epoxides, Olfactory receptors, Dicarboxylic acids, Rodenticides, Human female endocrine system


Application Date


Grant Date



Related Topics

Epoxides, Olfactory receptors, Dicarboxylic acids, Rodenticides, Human female endocrine system



Latest SenesTech News

16:05 EDT SenesTech Announces Record First Quarter 2022 Product Sales

May 12, 2022

News provided by Share this article Company Launches New Elevate Bait System™ with ContraPest® PHOENIX, May 12, 2022 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES , "SenesTech" or the "Company"),  ( ) the rodent fertility control experts and inventors of the only EPA registered contraceptive for male and female rats, ContraPest®, today announced record first quarter 2022 product sales, more than double compared to last year's first quarter. The Company continues to see strong growth from its recent marketing initiatives, including its award-winning "Operation Rat Race" campaign which has driven an increase in e-commerce sales, as well as accelerating close rates through its field sales team. Additionally, the Company has launched the novel and patent pending Elevate Bait System™ with ContraPest ("Elevate"), the first product of its kind specifically designed to address rat problems in above-ground locations. In addition to SenesTech's sales and marketing strategy to drive increased awareness and recognition of ContraPest, the Company continues to experience improving market conditions from favorable legislative changes, growing environmental sensitivity, and an emerging preference for "earth-friendly" choices. The sequential revenue growth during the first quarter represents eight out of the last nine quarters having double or 2X revenue growth since Chief Executive Officer Ken Siegel joined the company in 2019 to launch commercialization efforts. Following the EPAs approval of Elevate in March 2022, which was received ahead of internal expectations and allows for broad deployment options, the Company began its pre-launch marketing campaign. The product is available for sale with initial deliveries beginning next week to key agricultural and commercial accounts in most states. These customers have requested a system that can better meet their needs of addressing roof rats that reside above ground, especially in the rafters of barns, granaries and storage and manufacturing facilities. In preparation for the Company's EPA submission for Elevate, SenesTech conducted extensive trials to prove the effectiveness of the system, providing potential customers the necessary data to make informed purchasing decisions, which should help to accelerate adoption of the system. The Elevate system, with its suspended bait station is revolutionary within the pest control industry, which typically utilizes traditional bait boxes to deliver pesticides and other products. The system is designed to permit easy drop in and replacement of new 8 oz bottles of ContraPest, reducing servicing time and cost. "I am pleased with yet another quarter of record sales, more than doubling from the year ago period," said Ken Siegel, SenesTech's Chief Executive Officer. "Our commercial sales organization is doing a great job driving product awareness, lead generation and close rates, but equally important, we are driving down our customer acquisition costs and increasing our lifetime customer values. I believe the market is increasingly recognizing the benefits of ContraPest as an effective tool against rat infestation." Mr. Siegel continued, "In addition to continued adoption of our existing ContraPest product, I believe the introduction of Elevate will be a defining moment where innovation enables us to accelerate our penetration into a number of key markets, particularly agriculture. Customers in this market segment have repeatedly asked us to find a solution that allows us to target roof rats where they live, eat and breed which most times is in the rafters of their various buildings and structures. As the only bait station specifically designed to target roof rats in an elevated location, Elevate has the capability to be a game-changer for us in this market." "With growing market awareness and adoption for our solution highlighted by record quarterly sales, coupled with the introduction of the Elevate system, we are off to a strong start in fiscal 2022. I believe ContraPest is the right product for pest control with significant growth potential based on its efficacy, environmental and regulatory requirements, as well as social trends. While we look forward to the continuation of the recent trends in the quarters to come, we have in place the necessary elements to accelerate growth even more," Siegel concluded. First Quarter 2022 Highlights Revenue during Q1 2022 was approximately $195,000 compared to approximately $88,000 in Q1 2021, an increase of 122%. Gross profit during Q1 2022 was approximately $90,000 or 46% of total revenue, compared to approximately $38,000, or 43% of total revenue in Q1 2021. Net loss during Q1 2022 was $(2.3) million, compared with a net loss of $(1.8) million for Q1 2021. Adjusted EBITDA loss, which is a non-GAAP measure of operating performance, for Q1 2022 was $(2.0) million compared to $(1.6) million in Q1 2021. Cash at the end of March 2022 was approximately $7.2 million. Use of Non-GAAP Measure Adjusted EBITDA is a non-GAAP measure. However, this measure is not intended to be a substitute for those financial measures reported in accordance with GAAP. Adjusted EBITDA has been included because management believes that, when considered together with the GAAP figures, it provides meaningful information related to our operating performance and liquidity and can enhance an overall understanding of financial results and trends. Adjusted EBITDA may be calculated by us differently than other companies that disclose measures with the same or similar term. See our attached financials for a reconciliation of this non-GAAP measure to the nearest GAAP measure. Conference Call Details Date and Time: Thursday, May 12, 2022, at 5:00 pm ET Call-in Information: Interested parties can access the conference call by dialing (844) 308-3351 or (412) 317-5407. Live Webcast Information: Interested parties can access the conference call via a live Internet webcast, which is available in the Investor Relations section of the Company's website at . Replay: A teleconference replay of the call will be available for seven days at (877) 344-7529 or (412) 317-0088, replay access code 6656470. A webcast replay will be available in the Investor Relations section of the Company's website at  for 90 days. About SenesTech We are "The Pest Control Difference" for the 21st century. We are rodent fertility control specialists fueled by our passion to create a healthy environment by virtually eliminating rodent pest populations. We keep an inescapable truth in mind. Two rats and their descendants can be responsible for the birth of up to 15,000 pups after a year. We invented ContraPest®, the only U.S. EPA registered contraceptive for male and female rats. ContraPest® fits seamlessly into all integrated pest management programs, greatly improving the overall goal of effective rat management. We strive for clean cities, efficient businesses and happy households – with a product that was designed to be effective and sustainable without killing rats. At SenesTech, we don't just eliminate rats. We make a better world. For more information visit   and . Safe Harbor Statement This press release contains "forward-looking statements" within the meaning of federal securities laws, and we intend that such forward-looking statements be subject to the safe harbor created thereby. Such forward-looking statements include, among others, our expectation of a continued trend for municipalities specifying the use of fertility control in their requests for proposal; our belief the introduction of Elevate will be a defining moment where innovation enables us to accelerate our penetration into a number of key markets, particularly agriculture; our belief that deployments to new customers, such as wildlife preserves and correctional facilities, are expected to drive continued growth in the coming years; our belief that our enactment of package and promotional discounts, to accelerate initial adoption and first-time purchase will drive longer term purchase renewals as the benefits of ContraPest are recognized by customers; our belief that ContraPest is the right product for pest control with significant growth potential based on efficacy and environmental, regulatory, and social trends; our belief that 2021 provided a strong foundation for future growth; our drivers for accelerating revenue growth; our expectation as we look to 2022 and beyond that we will build on the foundation and momentum created in 2021, with two important additional drivers to watch: one, Elevate is expected to further accelerate our penetration into agricultural opportunities, as it provides an additional, often requested, method of delivery for ContraPest; and two, we are seeing enhanced interest from major PMPs to begin utilizing ContraPest as part of an integrated pest management program; and our belief that we are well positioned to continue to expand the strong track record of growth in the future. Forward-looking statements may describe future expectations, plans, results or strategies and are often, but not always, made through the use of words such as "believe," "may," "future," "plan," "will," "should," "expect," "anticipate," "eventually," "project," "estimate," "continuing," "intend" and similar words or phrases. You are cautioned that such statements are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those reflected by such forward-looking statements. Such factors include, among others, the impacts and implications of the COVID-19 pandemic, the successful commercialization of our products, market acceptance of our products, regulatory approval and regulation of our products and other factors and risks identified from time to time in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2021. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise. SENESTECH, INC.

SenesTech Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

SenesTech Rank

  • When was SenesTech founded?

    SenesTech was founded in 2002.

  • Where is SenesTech's headquarters?

    SenesTech's headquarters is located at 2225 East Gemini Drive, Flagstaff.

  • What is SenesTech's latest funding round?

    SenesTech's latest funding round is IPO.

  • Who are SenesTech's competitors?

    Competitors of SenesTech include Biolog, Intralytix, GangaGen, Bloomage BioTech, Unima and 13 more.

You May Also Like

Biolog Logo

Biolog specializes in microbial identification, phenotypic cell profiling, and metabolic fingerprinting for microbial and mammalian cells. The company’s products enable the identification of thousands of species of bacteria, yeast, and fungi, as well as the characterization of human cells and mitochondria. Biolog's products are available worldwide, either directly from the company or through its extensive network of international distributors. The company was founded in 1984 and is based in Hayward, California.

Hawaii Biotech

Hawaii Biotech (HBI) is a privately held biotechnology company focused on the research and development of vaccines for established and emerging infectious diseases. The company has developed expertise in the production of recombinant proteins applicable to the development of safe and effective vaccines. Lead vaccine candidates in clinical development target the West Nile virus and Dengue virus. Additional recombinant protein subunits vaccine candidates produced from this protein production platform are currently under development.

bcs Biotech S.p.A.

bcs Biotech SpA is a biotech company based in Cagliari, Italy. The activities of BCS Biotech have focused on the design and production of PCR kits for the medical, veterinary and food processing markets. The years of start-up and research have led to the development of products and efficient quality-oriented manufacturing facilities. Recently, BCS has introduced a diagnostic system on microchips.nMEDICA 2008n


SiTec Consulting was established in 1996, on the basis of long experience in pharmaceutical R&D. The company developed a range of expertise working with pharmaceutical and biotech companies in the United States and in Europe.n SiTec Consulting offers pharmaceutical and biotechnology companies a variety of services in the areas of preformulation, drug development, drug delivery and formulation technologies evaluation, regulatory and cGLP/cGMP compliance. The company can actively collaborate with start-up pharmaceutical and drug delivery companies to provide scientific and strategic support in the establishment of the new company's activities. The company emphasize open communication, active involvement with the client and continuous feedback.n Networking is one of the company's assets, allowing us to cover the complex demands of the R&D process. The company have access to laboratories and equipment and resources, located at the Bioindustry Park Canavese, and at selected universities and research centers in Europe. This aims to give the possibility to conduct and manage experimental parts of projects at the company's clients' request.n The company value the importance of high quality training. In addition to the hands-on experience the company can provide to the company's clients, SiTec is an authorized representative of the Center for Professional Advancement, a worldwide private institution dedicated to the provision of continuing technical and scientific education at a professional level.

Laureate Pharma

Laureate Pharma, Inc. is a full service contract manufacturing organization(CMO) providing development and cGMP manufacturing services in the company's FDA registered facilities in Princeton, New Jersey. The company is dedicated to supporting the development and commercialization of biopharmaceutical, drug and diagnostic products for pharmaceutical, diagnostic and biotech companies.The company aims to provide a range of product development and manufacturing services from cell line optimization and process design to development of full-scale cGMP protein production, purification and aseptic filling, in addition to corresponding testing, validation, analytical and regulatory support. The company's focus is on mammalian cell based monoclonal antibody and recombinant protein production for clinical and modest commercial supply.The company view the company's customers as partners and provide them with flexible solutions that reduce time to clinic and market. Focused on operational excellence, the company's highly experienced staff works with the company's customers to improve the quality of their products and processes.The company value the company's customers, stakeholders and associates. Therefore, the company measure the company's success by meeting the company's customers' needs, generating results in terms of quality, timeliness and on budget performance, as well as fostering an environment of trust, growth and diversity for the company's team.

Chef Solutions

Chef Solutions is a corporate entity consisting of the Orval Kent Foods Co. Orval Kent is a provider of prepared foods and meal solutions to the retail and food service industries.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.